Industry Research Reports
Home > Reports > Pharma & Healthcare > Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2031
- Description
- Table of Contents
- Table of Figures
- Related Reports
PDF Download
- Description
- Table of Contents
- Table of Figures
- Related Reports
- PDF Download
NAD+ Intravenous Therapy Market Size(US$)
CAGR 2025-2031
7.5%
Market Size,2031
USD 479
Million
Market Snapshot
Market Size in 2025 (Value)
US$ 311 million
Market Forecast in 2031(Value)
US$ 479 million
CAGR
7.5%
Years Considered
2020-2031
Base Year
2025
Forecast Period
2025-2031
Source: Secondary research, interviews with experts, and QYResearch analysis
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 479 million by 2031, at a CAGR of 7.5% (2025-2031), driven by critical product segments and diverse end‑use applications.
NAD+ IV Therapy is a wellness therapy that involves the intravenous administration of nicotinamide adenine dinucleotide (NAD+), a coenzyme crucial for cellular energy production and metabolic processes. This therapy is believed to boost energy levels, enhance cognitive function, and promote overall cellular repair by increasing NAD+ levels, which naturally decline with age.
From a downstream perspective, Clinic accounted for % of 2024 revenue, surging to US$ million by 2031 (CAGR: % from 2025–2031).
NAD+ Intravenous Therapy leading manufacturers including The Wellness Lab, Conciergemdla, Azivmedics, Reset IV, Thedripclub, Toronto Functional Medicine Centre, Mobileivmedics, Rocky Mountain Ivmedics, Seaside Skin Care, Premiumhealth, etc., dominate supply; the top five capture approximately % of global revenue, with The Wellness Lab leading 2024 sales at US$ million.
Regional Outlook:
North America rose from US$ million in 2024 to a forecast US$ million by 2031 (CAGR %).
Asia‑Pacific will expand from US$ million to US$ million (CAGR %), led by China (US$ million in 2024, % share rising to % by 2031), Japan (CAGR %), South Korea (CAGR %), and Southeast Asia (CAGR %).
Europe is set to grow from US$ million to US$ million (CAGR %), with Germany projected to hit US$ million by 2031 (CAGR %).
Report Includes:
This definitive report equips CEOs, marketing directors, and investors with a 360° view of the global NAD+ Intravenous Therapy market across value chain. It analyzes historical revenue data (2020–2024) and delivers forecasts through 2031, illuminating demand trends and growth drivers.
By segmenting the market by Type and by Application, the study quantifies market size, growth rates, niche opportunities, and substitution risks, and analyzes downstream customers distribution pattern.
Granular regional insights cover five major markets—North America, Europe, APAC, South America, and MEA—with in‑depth analysis of 20+ countries, detailing dominant products, competitive landscape, and downstream demand trends.
Critical competitive intelligence profiles players—revenue, margins, pricing strategies, and major customers—and dissects the top-player positioning across product lines, applications, and regions to reveal strategic strengths.
A concise Industry‑chain overview maps upstream, middlestream, and downstream distribution dynamics to identify strategic gaps and unmet demand.
Market Segmentation
By Company
- The Wellness Lab
- Conciergemdla
- Azivmedics
- Reset IV
- Thedripclub
- Toronto Functional Medicine Centre
- Mobileivmedics
- Rocky Mountain Ivmedics
- Seaside Skin Care
- Premiumhealth
- Effect Doctors
- Nadclinic
- Hydrate IV Bar
- LIVV Natural
- BioReset Medical
- IV Boost UK
Consumption by Region
- North America
- United States
- Canada
- Asia-Pacific
- China
- Japan
- South Korea
- Southeast Asia
- India
- Australia
- Rest of Asia-Pacific
- Europe
- Germany
- France
- U.K.
- Italy
- Netherlands
- Nordic Countries
- Rest of Europe
- Latin America
- Mexico
- Brazil
- Rest of Latin America
- Middle East & Africa
- Turkey
- Saudi Arabia
- UAE
- Rest of MEA
Segment by Type
- NAD+ Mixed Vitamin Injections
- Pure NAD+ Injection
Segment by Application
- Clinic
- Hospital
- Residential
Chapter Outline
Chapter 1: Defines the NAD+ Intravenous Therapy study scope, segments the market by Type and by Application, etc, highlights segment size and growth potential.
Chapter 2: Offers current market state, projects global revenue and sales to 2031, pinpointing high consumption regions and emerging market catalysts
Chapter 3: Dissects the player landscape—ranks by revenue and profitability, details Player performance by product type and evaluates concentration alongside M&A moves.
Chapter 4: Unlocks high margin product segments—compares revenue, ASP, and technology differentiators, highlighting growth niches and substitution risks
Chapter 5: Targets downstream market opportunities—evaluates market size by Application, identifies emerging use cases, and profiles leading customers by region and by Application.
Chapter 6: North America—breaks down market size by Type, by Application and country, profiles key players and assesses growth drivers and barriers.
Chapter 7: Europe—analyses regional market by Type, by Application and players, flagging drivers and barriers.
Chapter 8: Asia Pacific—quantifies market size by Type, by Application, and region/country, profiles top players, and uncovers high potential expansion areas.
Chapter 9: Central & South America—measures market size by Type, by Application, and country, profiles top players, and identifies investment opportunities and challenges.
Chapter 10: Middle East and Africa—evaluates market size by Type, by Application, and country, profiles key players, and outlines investment prospects and market hurdles
Chapter 11: Profiles players in depth—details product specs, revenue, margins; Top-tier players 2024 sales breakdowns by Product type, by Application, by region SWOT analysis, and recent strategic developments.
Chapter 12: Industry chain—analyses upstream, cost drivers, plus downstream channels.
Chapter 13: Market dynamics—explores drivers, restraints, regulatory impacts, and risk mitigation strategies.
Chapter 14: Actionable conclusions and strategic recommendations.
Why This Report:
Beyond standard market data, this analysis provides a clear profitability roadmap—empowering you to:
Allocate capital strategically to high growth regions (Chapters 6–10) and margin rich segments (Chapter 5).
Negotiate from strength with suppliers (Chapter 12) and customers (Chapter 5) using cost and demand intelligence.
Outmaneuver competitors with granular insights into their operations, margins, and strategies (Chapters 3 and 11).
Capitalize on the projected billion‑dollar opportunity with data‑driven regional and segment tactics (Chapter 12-14).
Leverage this 360° intelligence to turn market complexity into actionable competitive advantage.
QYResearch's Strengths
Unlike generic global market reports, this study combines macro-level industry trends with hyper-local operational intelligence, empowering data-driven decisions across the Compound Chocolate value chain, addressing:
Market entry risks/opportunities by region
We identify regional market threats and growth prospects to guide your overseas layout.
Product mix optimization based on local practices
We adjust product portfolios in line with local consumption habits.
Competitor tactics in fragmented vs. consolidated markets
We unpack rivals’ operation strategies for scattered and highly concentrated industries.
Full Research Coverage
We cover competition landscape, full supply chain and quantified market size data, and deliver tailor-made customized surveys to meet your unique business demands.
19 Years Industry Expertise
We own self-owned massive exclusive databases, backed by 19 years of global market research experience across thousands of sectors.
24/7 Fast Report Delivery
Our team operates 24 hours a day, 365 days a year, enabling ultra-fast report turnaround to respond to your research needs efficiently.
Localized Strategic Analysis
We integrate regional risk assessment, localized product optimization and competitor analysis to deliver actionable market strategies.
Market entry risks/opportunities by region
All data is cross-verified from multiple industry sources to deliver thorough, precise analysis that supports reliable corporate strategic decisions.
Market entry risks/opportunities by region
We provide responsive, dedicated after-sales support to resolve all follow-up inquiries about reports, data and industry interpretation.
Table of Contents
1 Study Coverage
1.1 Introduction to NAD+ Intravenous Therapy: Definition, Properties, and Key Attributes
1.2 Market Segmentation by Type
1.2.1 Global NAD+ Intravenous Therapy Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 NAD+ Mixed Vitamin Injections
1.2.3 Pure NAD+ Injection
1.3 Market Segmentation by Application
1.3.1 Global NAD+ Intravenous Therapy Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Clinic
1.3.3 Hospital
1.3.4 Residential
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Executive Summary
2.1 Global NAD+ Intravenous Therapy Revenue Estimates and Forecasts 2020-2031
2.2 Global NAD+ Intravenous Therapy Revenue by Region
2.2.1 Revenue Comparison: 2020 VS 2024 VS 2031
2.2.2 Historical and Forecasted Revenue by Region (2020-2031)
2.2.3 Global Revenue Market Share by Region (2020-2031)
2.2.4 Emerging Market Focus: Growth Drivers & Investment Trends
3 Competition by Players
3.1 Global NAD+ Intravenous Therapy Player Revenue Rankings and Profitability
3.1.1 Global Revenue (Value) by Players (2020-2025)
3.1.2 Global Key Player Revenue Ranking (2023 vs. 2024)
3.1.3 Revenue-Based Tier Segmentation (Tier 1, Tier 2, and Tier 3)
3.1.4 Gross Margin by Top Player (2020 VS 2024)
3.2 Global NAD+ Intravenous Therapy Companies Headquarters and Service Footprint
3.3 Main Product Type Market Size by Players
3.3.1 NAD+ Mixed Vitamin Injections Market Size by Players
3.3.2 Pure NAD+ Injection Market Size by Players
3.4 Global NAD+ Intravenous Therapy Market Concentration and Dynamics
3.4.1 Global Market Concentration (CR5 and HHI)
3.4.2 Entrant/Exit Impact Analysis
3.4.3 Strategic Moves: M&A, Expansion, R&D Investment
4 Global Product Segmentation Analysis
4.1 Global NAD+ Intravenous Therapy Revenue Trends by Type
4.1.1 Global Historical and Forecasted Revenue by Type (2020-2031)
4.1.2 Global Revenue Market Share by Type (2020-2031)
4.2 Key Product Attributes and Differentiation
4.3 Subtype Dynamics: Growth Leaders, Profitability and Risk
4.3.1 High-Growth Niches and Adoption Drivers
4.3.2 Profitability Hotspots and Cost Drivers
4.3.3 Substitution Threats
5 Global Downstream Application Analysis
5.1 Global NAD+ Intravenous Therapy Revenue by Application
5.1.1 Global Historical and Forecasted Revenue by Application (2020-2031)
5.1.2 Revenue Market Share by Application (2020-2031)
5.1.3 High-Growth Application Identification
5.1.4 Emerging Application Case Studies
5.2 Downstream Customer Analysis
5.2.1 Top Customers by Region
5.2.2 Top Customers by Application
6 North America
6.1 North America Market Size (2020-2031)
6.2 North America Key Players Revenue in 2024
6.3 North America NAD+ Intravenous Therapy Market Size by Type (2020-2031)
6.4 North America NAD+ Intravenous Therapy Market Size by Application (2020-2031)
6.5 North America Growth Accelerators and Market Barriers
6.6 North America NAD+ Intravenous Therapy Market Size by Country
6.6.1 North America Revenue Trends by Country
6.6.2 US
6.6.3 Canada
6.6.4 Mexico
7 Europe
7.1 Europe Market Size (2020-2031)
7.2 Europe Key Players Revenue in 2024
7.3 Europe NAD+ Intravenous Therapy Market Size by Type (2020-2031)
7.4 Europe NAD+ Intravenous Therapy Market Size by Application (2020-2031)
7.5 Europe Growth Accelerators and Market Barriers
7.6 Europe NAD+ Intravenous Therapy Market Size by Country
7.6.1 Europe Revenue Trends by Country
7.6.2 Germany
7.6.3 France
7.6.4 U.K.
7.6.5 Italy
7.6.6 Russia
8 Asia-Pacific
8.1 Asia-Pacific Market Size (2020-2031)
8.2 Asia-Pacific Key Players Revenue in 2024
8.3 Asia-Pacific NAD+ Intravenous Therapy Market Size by Type (2020-2031)
8.4 Asia-Pacific NAD+ Intravenous Therapy Market Size by Application (2020-2031)
8.5 Asia-Pacific Growth Accelerators and Market Barriers
8.6 Asia-Pacific NAD+ Intravenous Therapy Market Size by Region
8.6.1 Asia-Pacific Revenue Trends by Region
8.7 China
8.8 Japan
8.9 South Korea
8.10 Australia
8.11 India
8.12 Southeast Asia
8.12.1 Indonesia
8.12.2 Vietnam
8.12.3 Malaysia
8.12.4 Philippines
8.12.5 Singapore
9 Central and South America
9.1 Central and South America Market Size (2020-2031)
9.2 Central and South America Key Players Revenue in 2024
9.3 Central and South America NAD+ Intravenous Therapy Market Size by Type (2020-2031)
9.4 Central and South America NAD+ Intravenous Therapy Market Size by Application (2020-2031)
9.5 Central and South America Investment Opportunities and Key Challenges
9.6 Central and South America NAD+ Intravenous Therapy Market Size by Country
9.6.1 Central and South America Revenue Trends by Country (2020 VS 2024 VS 2031)
9.6.2 Brazil
9.6.3 Argentina
10 Middle East and Africa
10.1 Middle East and Africa Market Size (2020-2031)
10.2 Middle East and Africa Key Players Revenue in 2024
10.3 Middle East and Africa NAD+ Intravenous Therapy Market Size by Type (2020-2031)
10.4 Middle East and Africa NAD+ Intravenous Therapy Market Size by Application (2020-2031)
10.5 Middle East and Africa Investment Opportunities and Key Challenges
10.6 Middle East and Africa NAD+ Intravenous Therapy Market Size by Country
10.6.1 Middle East and Africa Revenue Trends by Country (2020 VS 2024 VS 2031)
10.6.2 GCC Countries
10.6.3 Israel
10.6.4 Egypt
10.6.5 South Africa
11 Corporate Profile
11.1 The Wellness Lab
11.1.1 The Wellness Lab Corporation Information
11.1.2 The Wellness Lab Business Overview
11.1.3 The Wellness Lab NAD+ Intravenous Therapy Product Features and Attributes
11.1.4 The Wellness Lab NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.1.5 The Wellness Lab NAD+ Intravenous Therapy Revenue by Product in 2024
11.1.6 The Wellness Lab NAD+ Intravenous Therapy Revenue by Application in 2024
11.1.7 The Wellness Lab NAD+ Intravenous Therapy Revenue by Geographic Area in 2024
11.1.8 The Wellness Lab NAD+ Intravenous Therapy SWOT Analysis
11.1.9 The Wellness Lab Recent Developments
11.2 Conciergemdla
11.2.1 Conciergemdla Corporation Information
11.2.2 Conciergemdla Business Overview
11.2.3 Conciergemdla NAD+ Intravenous Therapy Product Features and Attributes
11.2.4 Conciergemdla NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.2.5 Conciergemdla NAD+ Intravenous Therapy Revenue by Product in 2024
11.2.6 Conciergemdla NAD+ Intravenous Therapy Revenue by Application in 2024
11.2.7 Conciergemdla NAD+ Intravenous Therapy Revenue by Geographic Area in 2024
11.2.8 Conciergemdla NAD+ Intravenous Therapy SWOT Analysis
11.2.9 Conciergemdla Recent Developments
11.3 Azivmedics
11.3.1 Azivmedics Corporation Information
11.3.2 Azivmedics Business Overview
11.3.3 Azivmedics NAD+ Intravenous Therapy Product Features and Attributes
11.3.4 Azivmedics NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.3.5 Azivmedics NAD+ Intravenous Therapy Revenue by Product in 2024
11.3.6 Azivmedics NAD+ Intravenous Therapy Revenue by Application in 2024
11.3.7 Azivmedics NAD+ Intravenous Therapy Revenue by Geographic Area in 2024
11.3.8 Azivmedics NAD+ Intravenous Therapy SWOT Analysis
11.3.9 Azivmedics Recent Developments
11.4 Reset IV
11.4.1 Reset IV Corporation Information
11.4.2 Reset IV Business Overview
11.4.3 Reset IV NAD+ Intravenous Therapy Product Features and Attributes
11.4.4 Reset IV NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.4.5 Reset IV NAD+ Intravenous Therapy Revenue by Product in 2024
11.4.6 Reset IV NAD+ Intravenous Therapy Revenue by Application in 2024
11.4.7 Reset IV NAD+ Intravenous Therapy Revenue by Geographic Area in 2024
11.4.8 Reset IV NAD+ Intravenous Therapy SWOT Analysis
11.4.9 Reset IV Recent Developments
11.5 Thedripclub
11.5.1 Thedripclub Corporation Information
11.5.2 Thedripclub Business Overview
11.5.3 Thedripclub NAD+ Intravenous Therapy Product Features and Attributes
11.5.4 Thedripclub NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.5.5 Thedripclub NAD+ Intravenous Therapy Revenue by Product in 2024
11.5.6 Thedripclub NAD+ Intravenous Therapy Revenue by Application in 2024
11.5.7 Thedripclub NAD+ Intravenous Therapy Revenue by Geographic Area in 2024
11.5.8 Thedripclub NAD+ Intravenous Therapy SWOT Analysis
11.5.9 Thedripclub Recent Developments
11.6 Toronto Functional Medicine Centre
11.6.1 Toronto Functional Medicine Centre Corporation Information
11.6.2 Toronto Functional Medicine Centre Business Overview
11.6.3 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Product Features and Attributes
11.6.4 Toronto Functional Medicine Centre NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.6.5 Toronto Functional Medicine Centre Recent Developments
11.7 Mobileivmedics
11.7.1 Mobileivmedics Corporation Information
11.7.2 Mobileivmedics Business Overview
11.7.3 Mobileivmedics NAD+ Intravenous Therapy Product Features and Attributes
11.7.4 Mobileivmedics NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.7.5 Mobileivmedics Recent Developments
11.8 Rocky Mountain Ivmedics
11.8.1 Rocky Mountain Ivmedics Corporation Information
11.8.2 Rocky Mountain Ivmedics Business Overview
11.8.3 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Product Features and Attributes
11.8.4 Rocky Mountain Ivmedics NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.8.5 Rocky Mountain Ivmedics Recent Developments
11.9 Seaside Skin Care
11.9.1 Seaside Skin Care Corporation Information
11.9.2 Seaside Skin Care Business Overview
11.9.3 Seaside Skin Care NAD+ Intravenous Therapy Product Features and Attributes
11.9.4 Seaside Skin Care NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.9.5 Seaside Skin Care Recent Developments
11.10 Premiumhealth
11.10.1 Premiumhealth Corporation Information
11.10.2 Premiumhealth Business Overview
11.10.3 Premiumhealth NAD+ Intravenous Therapy Product Features and Attributes
11.10.4 Premiumhealth NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.10.5 Company Ten Recent Developments
11.11 Effect Doctors
11.11.1 Effect Doctors Corporation Information
11.11.2 Effect Doctors Business Overview
11.11.3 Effect Doctors NAD+ Intravenous Therapy Product Features and Attributes
11.11.4 Effect Doctors NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.11.5 Effect Doctors Recent Developments
11.12 Nadclinic
11.12.1 Nadclinic Corporation Information
11.12.2 Nadclinic Business Overview
11.12.3 Nadclinic NAD+ Intravenous Therapy Product Features and Attributes
11.12.4 Nadclinic NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.12.5 Nadclinic Recent Developments
11.13 Hydrate IV Bar
11.13.1 Hydrate IV Bar Corporation Information
11.13.2 Hydrate IV Bar Business Overview
11.13.3 Hydrate IV Bar NAD+ Intravenous Therapy Product Features and Attributes
11.13.4 Hydrate IV Bar NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.13.5 Hydrate IV Bar Recent Developments
11.14 LIVV Natural
11.14.1 LIVV Natural Corporation Information
11.14.2 LIVV Natural Business Overview
11.14.3 LIVV Natural NAD+ Intravenous Therapy Product Features and Attributes
11.14.4 LIVV Natural NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.14.5 LIVV Natural Recent Developments
11.15 BioReset Medical
11.15.1 BioReset Medical Corporation Information
11.15.2 BioReset Medical Business Overview
11.15.3 BioReset Medical NAD+ Intravenous Therapy Product Features and Attributes
11.15.4 BioReset Medical NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.15.5 BioReset Medical Recent Developments
11.16 IV Boost UK
11.16.1 IV Boost UK Corporation Information
11.16.2 IV Boost UK Business Overview
11.16.3 IV Boost UK NAD+ Intravenous Therapy Product Features and Attributes
11.16.4 IV Boost UK NAD+ Intravenous Therapy Revenue and Gross Margin (2020-2025)
11.16.5 IV Boost UK Recent Developments
12 NAD+ Intravenous TherapyIndustry Chain Analysis
12.1 NAD+ Intravenous Therapy Industry Chain
12.2 Upstream Analysis
12.2.1 Upstream Key Suppliers
12.3 Middlestream Analysis
12.4 Downstream Sales Model and Distribution Networks
12.4.1 Sales Channels
12.4.2 Distributors
13 NAD+ Intravenous Therapy Market Dynamics
13.1 Industry Trends and Evolution
13.2 Market Growth Drivers and Emerging Opportunities
13.3 Market Challenges, Risks, and Restraints
14 Key Findings in the Global NAD+ Intravenous Therapy Study
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.1.1 Research Programs/Design
15.1.1.2 Market Size Estimation
15.1.1.3 Market Breakdown and Data Triangulation
15.1.2 Data Source
15.1.2.1 Secondary Sources
15.1.2.2 Primary Sources
15.2 Author Details
Table of Figures
List of Tables
Table 1. Global NAD+ Intravenous Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Table 2. Global NAD+ Intravenous Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Table 3. Global NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 4. Global NAD+ Intravenous Therapy Revenue by Region (2020-2025) & (US$ Million)
Table 5. Global NAD+ Intravenous Therapy Revenue by Region (2026-2031) & (US$ Million)
Table 6. Emerging Market Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 7. Global NAD+ Intravenous Therapy Revenue by Players (2020-2025) & (US$ Million)
Table 8. Global NAD+ Intravenous Therapy Revenue Market Share by Players (2020-2025)
Table 9. Global Key Players’Ranking Shift (2023 vs. 2024) (Based on Revenue)
Table 10. Global NAD+ Intravenous Therapy by Player Tier (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in NAD+ Intravenous Therapy as of 2024)
Table 11. Global NAD+ Intravenous Therapy Average Gross Margin (%) by Player (2020 VS 2024)
Table 12. Global NAD+ Intravenous Therapy Companies Headquarters
Table 13. Global NAD+ Intravenous Therapy Market Concentration Ratio (CR5 and HHI)
Table 14. Key Market Entrant/Exit (2020-2024) – Drivers & Impact Analysis
Table 15. Key Mergers & Acquisitions, Expansion Plans, R&D Investment
Table 16. Global NAD+ Intravenous Therapy Revenue by Type (2020-2025) & (US$ Million)
Table 17. Global NAD+ Intravenous Therapy Revenue by Type (2026-2031) & (US$ Million)
Table 18. Key Product Attributes and Differentiation
Table 19. Global NAD+ Intravenous Therapy Revenue by Application (2020-2025) & (US$ Million)
Table 20. Global NAD+ Intravenous Therapy Revenue by Application (2026-2031) & (US$ Million)
Table 21. NAD+ Intravenous Therapy High-Growth Sectors Demand CAGR (2024-2031)
Table 22. Top Customers by Region
Table 23. Top Customers by Application
Table 24. North America NAD+ Intravenous Therapy Growth Accelerators and Market Barriers
Table 25. North America NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 26. Europe NAD+ Intravenous Therapy Growth Accelerators and Market Barriers
Table 27. Europe NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Country: 2020 VS 2024 VS 2031 (US$ Million)
Table 28. Asia-Pacific NAD+ Intravenous Therapy Growth Accelerators and Market Barriers
Table 29. Asia-Pacific NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Table 30. Central and South America NAD+ Intravenous Therapy Investment Opportunities and Key Challenges
Table 31. Central and South America NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 32. Middle East and Africa NAD+ Intravenous Therapy Investment Opportunities and Key Challenges
Table 33. Middle East and Africa NAD+ Intravenous Therapy Revenue Grow Rate (CAGR) by Country (2020 VS 2024 VS 2031) (US$ Million)
Table 34. The Wellness Lab Corporation Information
Table 35. The Wellness Lab Description and Major Businesses
Table 36. The Wellness Lab Product Features and Attributes
Table 37. The Wellness Lab Revenue (US$ Million) and Gross Margin (2020-2025)
Table 38. The Wellness Lab Revenue Proportion by Product in 2024
Table 39. The Wellness Lab Revenue Proportion by Application in 2024
Table 40. The Wellness Lab Revenue Proportion by Geographic Area in 2024
Table 41. The Wellness Lab NAD+ Intravenous Therapy SWOT Analysis
Table 42. The Wellness Lab Recent Developments
Table 43. Conciergemdla Corporation Information
Table 44. Conciergemdla Description and Major Businesses
Table 45. Conciergemdla Product Features and Attributes
Table 46. Conciergemdla Revenue (US$ Million) and Gross Margin (2020-2025)
Table 47. Conciergemdla Revenue Proportion by Product in 2024
Table 48. Conciergemdla Revenue Proportion by Application in 2024
Table 49. Conciergemdla Revenue Proportion by Geographic Area in 2024
Table 50. Conciergemdla NAD+ Intravenous Therapy SWOT Analysis
Table 51. Conciergemdla Recent Developments
Table 52. Azivmedics Corporation Information
Table 53. Azivmedics Description and Major Businesses
Table 54. Azivmedics Product Features and Attributes
Table 55. Azivmedics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 56. Azivmedics Revenue Proportion by Product in 2024
Table 57. Azivmedics Revenue Proportion by Application in 2024
Table 58. Azivmedics Revenue Proportion by Geographic Area in 2024
Table 59. Azivmedics NAD+ Intravenous Therapy SWOT Analysis
Table 60. Azivmedics Recent Developments
Table 61. Reset IV Corporation Information
Table 62. Reset IV Description and Major Businesses
Table 63. Reset IV Product Features and Attributes
Table 64. Reset IV Revenue (US$ Million) and Gross Margin (2020-2025)
Table 65. Reset IV Revenue Proportion by Product in 2024
Table 66. Reset IV Revenue Proportion by Application in 2024
Table 67. Reset IV Revenue Proportion by Geographic Area in 2024
Table 68. Reset IV NAD+ Intravenous Therapy SWOT Analysis
Table 69. Reset IV Recent Developments
Table 70. Thedripclub Corporation Information
Table 71. Thedripclub Description and Major Businesses
Table 72. Thedripclub Product Features and Attributes
Table 73. Thedripclub Revenue (US$ Million) and Gross Margin (2020-2025)
Table 74. Thedripclub Revenue Proportion by Product in 2024
Table 75. Thedripclub Revenue Proportion by Application in 2024
Table 76. Thedripclub Revenue Proportion by Geographic Area in 2024
Table 77. Thedripclub NAD+ Intravenous Therapy SWOT Analysis
Table 78. Thedripclub Recent Developments
Table 79. Toronto Functional Medicine Centre Corporation Information
Table 80. Toronto Functional Medicine Centre Description and Major Businesses
Table 81. Toronto Functional Medicine Centre Product Features and Attributes
Table 82. Toronto Functional Medicine Centre Revenue (US$ Million) and Gross Margin (2020-2025)
Table 83. Toronto Functional Medicine Centre Recent Developments
Table 84. Mobileivmedics Corporation Information
Table 85. Mobileivmedics Description and Major Businesses
Table 86. Mobileivmedics Product Features and Attributes
Table 87. Mobileivmedics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 88. Mobileivmedics Recent Developments
Table 89. Rocky Mountain Ivmedics Corporation Information
Table 90. Rocky Mountain Ivmedics Description and Major Businesses
Table 91. Rocky Mountain Ivmedics Product Features and Attributes
Table 92. Rocky Mountain Ivmedics Revenue (US$ Million) and Gross Margin (2020-2025)
Table 93. Rocky Mountain Ivmedics Recent Developments
Table 94. Seaside Skin Care Corporation Information
Table 95. Seaside Skin Care Description and Major Businesses
Table 96. Seaside Skin Care Product Features and Attributes
Table 97. Seaside Skin Care Revenue (US$ Million) and Gross Margin (2020-2025)
Table 98. Seaside Skin Care Recent Developments
Table 99. Premiumhealth Corporation Information
Table 100. Premiumhealth Description and Major Businesses
Table 101. Premiumhealth Product Features and Attributes
Table 102. Premiumhealth Revenue (US$ Million) and Gross Margin (2020-2025)
Table 103. Premiumhealth Recent Developments
Table 104. Effect Doctors Corporation Information
Table 105. Effect Doctors Description and Major Businesses
Table 106. Effect Doctors Product Features and Attributes
Table 107. Effect Doctors Revenue (US$ Million) and Gross Margin (2020-2025)
Table 108. Effect Doctors Recent Developments
Table 109. Nadclinic Corporation Information
Table 110. Nadclinic Description and Major Businesses
Table 111. Nadclinic Product Features and Attributes
Table 112. Nadclinic Revenue (US$ Million) and Gross Margin (2020-2025)
Table 113. Nadclinic Recent Developments
Table 114. Hydrate IV Bar Corporation Information
Table 115. Hydrate IV Bar Description and Major Businesses
Table 116. Hydrate IV Bar Product Features and Attributes
Table 117. Hydrate IV Bar Revenue (US$ Million) and Gross Margin (2020-2025)
Table 118. Hydrate IV Bar Recent Developments
Table 119. LIVV Natural Corporation Information
Table 120. LIVV Natural Description and Major Businesses
Table 121. LIVV Natural Product Features and Attributes
Table 122. LIVV Natural Revenue (US$ Million) and Gross Margin (2020-2025)
Table 123. LIVV Natural Recent Developments
Table 124. BioReset Medical Corporation Information
Table 125. BioReset Medical Description and Major Businesses
Table 126. BioReset Medical Product Features and Attributes
Table 127. BioReset Medical Revenue (US$ Million) and Gross Margin (2020-2025)
Table 128. BioReset Medical Recent Developments
Table 129. IV Boost UK Corporation Information
Table 130. IV Boost UK Description and Major Businesses
Table 131. IV Boost UK Product Features and Attributes
Table 132. IV Boost UK Revenue (US$ Million) and Gross Margin (2020-2025)
Table 133. IV Boost UK Recent Developments
Table 134. Raw Materials Key Suppliers
Table 135. Distributors List
Table 136. Market Trends and Market Evolution
Table 137. Market Drivers and Opportunities
Table 138. Market Challenges, Risks, and Restraints
Table 139. Research Programs/Design for This Report
Table 140. Key Data Information from Secondary Sources
Table 141. Key Data Information from Primary Sources
List of Figures
Figure 1. NAD+ Intravenous Therapy Product Picture
Figure 2. Global NAD+ Intravenous Therapy Market Size Growth Rate by Type, 2020 VS 2024 VS 2031 (US$ Million)
Figure 3. NAD+ Mixed Vitamin Injections Product Picture
Figure 4. Pure NAD+ Injection Product Picture
Figure 5. Global NAD+ Intravenous Therapy Market Size Growth Rate by Application, 2020 VS 2024 VS 2031 (US$ Million)
Figure 6. Clinic
Figure 7. Hospital
Figure 8. Residential
Figure 9. NAD+ Intravenous Therapy Report Years Considered
Figure 10. Global NAD+ Intravenous Therapy Revenue, (US$ Million), 2020 VS 2024 VS 2031
Figure 11. Global NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 12. Global NAD+ Intravenous Therapy Revenue (CAGR) by Region: 2020 VS 2024 VS 2031 (US$ Million)
Figure 13. Global NAD+ Intravenous Therapy Revenue Market Share by Region (2020-2031)
Figure 14. Global NAD+ Intravenous Therapy Revenue Market Share Ranking (2024)
Figure 15. Tier Distribution by Revenue Contribution (2020 VS 2024)
Figure 16. NAD+ Mixed Vitamin Injections Revenue Market Share by Player in 2024
Figure 17. Pure NAD+ Injection Revenue Market Share by Player in 2024
Figure 18. Global NAD+ Intravenous Therapy Revenue Market Share by Type (2020-2031)
Figure 19. Global NAD+ Intravenous Therapy Revenue Market Share by Application (2020-2031)
Figure 20. North America NAD+ Intravenous Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 21. North America Top 5 Players NAD+ Intravenous Therapy Revenue (US$ Million) in 2024
Figure 22. North America NAD+ Intravenous Therapy Revenue (US$ Million) by Type (2020 - 2031)
Figure 23. North America NAD+ Intravenous Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 24. US NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 25. Canada NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 26. Mexico NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 27. Europe NAD+ Intravenous Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 28. Europe Top 5 Players NAD+ Intravenous Therapy Revenue (US$ Million) in 2024
Figure 29. Europe NAD+ Intravenous Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 30. Europe NAD+ Intravenous Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 31. Germany NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 32. France NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 33. U.K. NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 34. Italy NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 35. Russia NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 36. Asia-Pacific NAD+ Intravenous Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 37. Asia-Pacific Top 8 Players NAD+ Intravenous Therapy Revenue (US$ Million) in 2024
Figure 38. Asia-Pacific NAD+ Intravenous Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 39. Asia-Pacific NAD+ Intravenous Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 40. Indonesia NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 41. Japan NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 42. South Korea NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 43. Australia NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 44. India NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 45. Indonesia NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 46. Vietnam NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 47. Malaysia NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 48. Philippines NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 49. Singapore NAD+ Intravenous Therapy Revenue (2020-2031) & (US$ Million)
Figure 50. Central and South America NAD+ Intravenous Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 51. Central and South America Top 5 Players NAD+ Intravenous Therapy Revenue (US$ Million) in 2024
Figure 52. Central and South America NAD+ Intravenous Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 53. Central and South America NAD+ Intravenous Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 54. Brazil NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 55. Argentina NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 56. Middle East and Africa NAD+ Intravenous Therapy Revenue YoY (2020-2031) & (US$ Million)
Figure 57. Middle East and Africa Top 5 Players NAD+ Intravenous Therapy Revenue (US$ Million) in 2024
Figure 58. South America NAD+ Intravenous Therapy Revenue (US$ Million) by Type (2020-2031)
Figure 59. Middle East and Africa NAD+ Intravenous Therapy Revenue (US$ Million) by Application (2020-2031)
Figure 60. GCC Countries NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 61. Israel NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 62. Egypt NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 63. South Africa NAD+ Intravenous Therapy Revenue (2020-2025) & (US$ Million)
Figure 64. NAD+ Intravenous Therapy Industry Chain Mapping
Figure 65. Channels of Distribution (Direct Vs Distribution)
Figure 66. Bottom-up and Top-down Approaches for This Report
Figure 67. Data Triangulation
Figure 68. Key Executives Interviewed
Related Reports
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published Date: 2024-11-11
Pages: 154
USD 4900.00
(Single User License)
Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published Date: 2024-11-11
Pages: 131
USD 4350.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published Date: 2024-11-11
Pages: 100
USD 2900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published Date: 2025-03-13
Pages: 97
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 125
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published Date: 2025-03-13
Pages: 105
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 117
USD 2900.00
(Single User License)
NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published Date: 2026-01-31
Pages: 105
USD 3950.00
(Single User License)
Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published Date: 2026-03-26
Pages: 94
USD 4250.00
(Single User License)
Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published Date: 2026-03-26
Pages: 133
USD 4900.00
(Single User License)
Global NAD+ Intravenous Therapy Market Insights, Forecast to 2030
The global NAD+ Intravenous Therapy market is projected to grow from US$ 291 million in 2024 to US$ 449 million by 2030, at a Compound Annual Growth Rate (CAGR) of 7.5% during the forecast period.
Published: 2024-11-11
Pages: 154
USD 4900.00 (Single User License)Global and United States NAD+ Intravenous Therapy Market Report & Forecast 2024-2030
The global NAD+ Intravenous Therapy revenue was US$ 281 million in 2023 and is forecast to a readjusted size of US$ 449 million by 2030 with a CAGR of 7.5% during the review period (2024-2030).
Published: 2024-11-11
Pages: 131
USD 4350.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2024
The global NAD+ Intravenous Therapy market was valued at US$ 281 million in 2023 and is anticipated to reach US$ 449 million by 2030, witnessing a CAGR of 7.5% during the forecast period 2024-2030.
Published: 2024-11-11
Pages: 100
USD 2900.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2025
The global market for NAD+ Intravenous Therapy was valued at US$ 291 million in the year 2024 and is projected to reach a revised size of US$ 479 million by 2031, growing at a CAGR of 7.5% during the forecast period.
Published: 2025-03-13
Pages: 97
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2025-2031
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 125
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2025-2031
The global NAD+ Intravenous Therapy market size was US$ 291 million in 2024 and is forecast to a readjusted size of US$ 479 million by 2031 with a CAGR of 7.5% during the forecast period 2025-2031.
Published: 2025-03-13
Pages: 105
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Research Report 2026
The global NAD+ Intravenous Therapy market was valued at US$ 99 million in 2025 and is anticipated to reach US$ 171 million by 2032, at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 117
USD 2900.00 (Single User License)NAD+ Intravenous Therapy - Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032
The global market for NAD+ Intravenous Therapy was estimated to be worth US$ 99 million in 2025 and is projected to reach US$ 171 million, growing at a CAGR of 8.3% from 2026 to 2032.
Published: 2026-01-31
Pages: 105
USD 3950.00 (Single User License)Global NAD+ Intravenous Therapy Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
The global NAD+ Intravenous Therapy market size was US$ 99 million in 2025 and is forecast to reach a readjusted size of US$ 171 million by 2032 with a CAGR of 8.3% during the forecast period 2026-2032.
Published: 2026-03-26
Pages: 94
USD 4250.00 (Single User License)Global NAD+ Intravenous Therapy Market Outlook, In‑Depth Analysis & Forecast to 2032
The global NAD+ Intravenous Therapy market is projected to grow from US$ 99 million in 2025 to US$ 171 million by 2032, at a CAGR of 8.3% (2026-2032), driven by critical product segments and diverse end‑use applications.
Published: 2026-03-26
Pages: 133
USD 4900.00 (Single User License)
CHOOSE LICENSE TYPE
USD 4900.00
USD 7350.00
USD 9800.00
Add to Cart
Buy Now
HAVE A QUESTION?
General Email:
REPORT COVERAGE
Market Segmentation
QYResearch's Strengths
TABLE OF CONTENTS
TABLE OF FIGURES
RLEATED REPORTS
Interest In This Report?
Get A Free Sample
Pre-Order Enquiry
OR
Need a Tailored Report?
Customize this report to your needs.
Customize This Report
Fact Checked
Cite this Research